These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 26006330)

  • 1. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer.
    Jain A; Jain SK
    Drug Dev Ind Pharm; 2016 Jan; 42(1):136-149. PubMed ID: 26006330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
    Tong L; Chen W; Wu J; Li H
    Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Matrix Gla Protein (MGP) Expression in Paclitaxel and Topotecan Resistant Ovarian Cancer Cell Lines.
    Sterzyńska K; Klejewski A; Wojtowicz K; Świerczewska M; Andrzejewska M; Rusek D; Sobkowski M; Kędzia W; Brązert J; Nowicki M; Januchowski R
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved Therapeutic Efficacy of Topotecan Against A549 Lung Cancer Cells with Folate-targeted Topotecan Liposomes.
    Zhang J; Shi W; Xue G; Ma Q; Cui H; Zhang L
    Curr Drug Metab; 2020; 21(11):902-909. PubMed ID: 32851958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes.
    Niu R; Zhao P; Wang H; Yu M; Cao S; Zhang F; Chang J
    J Drug Target; 2011 Jun; 19(5):373-81. PubMed ID: 20677917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
    Dadashzadeh S; Vali AM; Rezaie M
    Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro &in vivo targeting behaviors of biotinylated Pluronic F127/poly(lactic acid) nanoparticles through biotin-avidin interaction.
    Xiong XY; Guo L; Gong YC; Li ZL; Li YP; Liu ZY; Zhou M
    Eur J Pharm Sci; 2012 Aug; 46(5):537-44. PubMed ID: 22538053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo pharmacokinetics, biodistribution and anti-tumor effect of paclitaxel-loaded targeted chitosan-based polymeric micelle.
    Rezazadeh M; Emami J; Hasanzadeh F; Sadeghi H; Minaiyan M; Mostafavi A; Rostami M; Lavasanifar A
    Drug Deliv; 2016 Jun; 23(5):1707-17. PubMed ID: 25188785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-loaded paclitaxel/rapamycin liposomes: Development, characterization and in vitro and in vivo evaluation for breast cancer therapy.
    Eloy JO; Petrilli R; Topan JF; Antonio HMR; Barcellos JPA; Chesca DL; Serafini LN; Tiezzi DG; Lee RJ; Marchetti JM
    Colloids Surf B Biointerfaces; 2016 May; 141():74-82. PubMed ID: 26836480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The enhanced longevity and liver targetability of Paclitaxel by hybrid liposomes encapsulating Paclitaxel-conjugated gold nanoparticles.
    Bao QY; Zhang N; Geng DD; Xue JW; Merritt M; Zhang C; Ding Y
    Int J Pharm; 2014 Dec; 477(1-2):408-15. PubMed ID: 25455782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
    Zucker D; Barenholz Y
    J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel-loaded stealth liposomes: Development, characterization, pharmacokinetics, and biodistribution.
    Xu Y; Meng H
    Artif Cells Nanomed Biotechnol; 2016; 44(1):350-5. PubMed ID: 25162671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
    Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB
    Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery.
    Chu B; Qu Y; Huang Y; Zhang L; Chen X; Long C; He Y; Ou C; Qian Z
    Int J Pharm; 2016 Mar; 500(1-2):345-59. PubMed ID: 26794876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity.
    Patankar NA; Pritchard J; van Grinsven M; Osooly M; Bally MB
    Clin Cancer Res; 2013 Feb; 19(4):865-77. PubMed ID: 23303216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity.
    Parmakhtiar B; Burger RA; Kim JH; Fruehauf JP
    Mol Cancer Res; 2019 Aug; 17(8):1675-1686. PubMed ID: 31088908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and evaluation of well-tolerated and tumor-penetrating polymeric micelle-based dry powders for inhaled anti-cancer chemotherapy.
    Rosière R; Van Woensel M; Mathieu V; Langer I; Mathivet T; Vermeersch M; Amighi K; Wauthoz N
    Int J Pharm; 2016 Mar; 501(1-2):148-59. PubMed ID: 26850313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.
    Tsunetoh S; Terai Y; Sasaki H; Tanabe A; Tanaka Y; Sekijima T; Fujioka S; Kawaguchi H; Kanemura M; Yamashita Y; Ohmichi M
    Cancer Biol Ther; 2010 Dec; 10(11):1137-46. PubMed ID: 20935474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.